Evidence map›Paper›PMID 40802126›Full record

ArticleNatural products and bioprospecting2025

Correction: Xiaoyankangjun tablet alleviates dextran sulfate sodium‑induced colitis in mice by regulating gut microbiota and JAK2/STAT3 pathway.

Suqin Yang, Jingtao Huang, Wenjing Tan, Xiankun Xia, Dali Gan, Yalei Ren, Hanwen Su, Meixian Xiang

Abstract readPublished Erratum
In one paragraph

Article in Natural products and bioprospecting, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Suqin Yang *School of Pharmaceutical Sciences, South-Central Minzu University, Wuhan, 430074, Hubei, People's Republic of China.
Jingtao Huang *Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China.
Wenjing Tan *School of Pharmaceutical Sciences, South-Central Minzu University, Wuhan, 430074, Hubei, People's Republic of China.
Xiankun XiaSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan, 430074, Hubei, People's Republic of China.
Dali GanSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan, 430074, Hubei, People's Republic of China.
Yalei RenSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan, 430074, Hubei, People's Republic of China.
Hanwen SuDepartment of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China. Suhanwen-1@163.com.
Meixian XiangSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan, 430074, Hubei, People's Republic of China. xiangmeixian@mail.scuec.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40802126
PMCPMC12350995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.